Trial Profile
A double blind, randomised, three-period, crossover, placebo controlled study to evaluate the effects of supratherapeutic dose of Doravirine on the heart rate QTc interval in healthy adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Aug 2017
Price :
$35
*
At a glance
- Drugs Doravirine (Primary) ; Moxifloxacin
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 17 Aug 2017 New trial record
- 07 Aug 2017 Results published in the Clinical Drug Investigation